Flerie AB (OSTO:FLERIE) FCF Margin % : -17,200.00% (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Flerie AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Flerie AB's Free Cash Flow for the three months ended in Jun. 2024 was kr-17.20 Mil. Flerie AB's Revenue for the three months ended in Jun. 2024 was kr0.10 Mil. Therefore, Flerie AB's FCF Margin % for the quarter that ended in Jun. 2024 was -17,200.00%.

As of today, Flerie AB's current FCF Yield % is -4.36%.

The historical rank and industry rank for Flerie AB's FCF Margin % or its related term are showing as below:

OSTO:FLERIE' s FCF Margin % Range Over the Past 10 Years
Min: -204454.29 Med: -38846.91 Max: -18.19
Current: -1332.41

During the past 10 years, the highest FCF Margin % of Flerie AB was -18.19%. The lowest was -204454.29%. And the median was -38846.91%.

OSTO:FLERIE's FCF Margin % is ranked worse than
78% of 1050 companies
in the Biotechnology industry
Industry Median: -143.325 vs OSTO:FLERIE: -1332.41

Flerie AB FCF Margin % Historical Data

The historical data trend for Flerie AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flerie AB FCF Margin % Chart

Flerie AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-96,682.95

-204,454.29

-38.95

Flerie AB Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial															82.02	-	-	-310.94	-17,200.00

Competitive Comparison of Flerie AB's FCF Margin %

For the Biotechnology subindustry, Flerie AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Flerie AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Flerie AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Flerie AB's FCF Margin % falls into.

Flerie AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Flerie AB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-37.977	/	97.505
	=	-38.95 %

Flerie AB's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-17.2	/	0.1
	=	-17,200.00 %

Flerie AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Flerie AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Flerie AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Flerie AB (OSTO:FLERIE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

1NP0:Germany

Address

Berzelius vag 13, Solna, SWE, 171 65

Website

https://www.indexpharma.com

InDex Pharmaceuticals Holding AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The company's main asset is the drug candidate cobitolimod, which is being evaluated in the phase III study as a treatment for moderate to severe ulcerative colitis - a disabling, chronic inflammation of the colon. It has also developed a platform of patent-protected substances, so-called DNA-based Immunomodulatory Sequences, with the potential to be used in the treatment of various immunological diseases.

Flerie AB Headlines

No Headlines